Lung transplantation outcomes after crossing low-level donor specific antibodies without planned augmented immunosuppression.
antibody mediated rejection
chronic lung allograft dysfunction
donor specific antibodies
lung transplantation
primary graft dysfunction
survival
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
26
06
2021
received:
10
04
2021
accepted:
27
07
2021
pubmed:
9
8
2021
medline:
3
2
2022
entrez:
8
8
2021
Statut:
ppublish
Résumé
It is unknown whether some donor specific antibodies (DSA) can be crossed at the time of lung transplant without desensitization or augmented induction immunosuppression. This study assessed whether crossing low-level pre-transplant DSA (defined as mean fluorescence intensity [MFI] 1000-6000) without augmented immunosuppression is associated with worse retransplant-free or chronic lung allograft dysfunction (CLAD)-free survival. Of the 458 included recipients, low-level pre-transplant DSA was crossed in 39 (8.6%) patients. The median follow-up time was 2.2 years. There were 15 (38.5%) patients with Class I DSA and 24 (61.5%) with Class II DSA. There was no difference in adjusted overall retransplant-free survival between recipients where pre-transplant DSA was and was not crossed (HR: .98 [95% CI = .49-1.99], P = .96). There was also no difference in CLAD-free survival (HR: .71 [95% CI = .38-1.33], P = .28). There was no difference in Grade 3 PGD at 72 h (OR: 1.13 [95% CI = .52-2.48], P = .75) or definite or probable AMR (HR: 2.22 [95% CI = .64-7.61], P = .21). Lung transplantation in the presence of low-level DSA without planned augmented immunosuppression is not associated with worse overall or CLAD-free survival among recipients with intermediate-term follow-up.
Substances chimiques
HLA Antigens
0
Isoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14447Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Tague LK, Witt CA, Byers DE, et al. Association between allosensitization and waiting list outcomes among adult lung transplant candidates in the United States. Ann Am Thorac Soc. 2019;16:846-885.
Courtwright AM, Kamoun M, Kearns J, Diamond JM, Golberg HJ. The impact of HLA-DR mismatch status on retransplant-free survival and bronchiolitis obliterans syndrome-free survival among sensitized lung transplant recipients. J Heart Lung Transplant. 2020;39:1455-1462.
Aversa M, Darley DR, Hirji A, et al. Approaches to the management of sensitized lung transplant candidates: findings from an international survey. J Heart Lung Transplant. 2020;39:S315.
Snyder LD, Gray AL, Reynolds JM, et al. Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant. 2014;14:849-856.
Tinckam KJ, Keshavjee S, Chaparro C, et al. Survival in sensitized lung transplant recipients with perioperative desensitization. Am J Transplant. 2015;15:417-426.
Courtwright AM, Cao S, Wood I, et al. Clinical outcomes of lung transplantation in the presence of donor-specific antibodies. Ann Am Thorac Soc. 2019;16:1131-1137.
Tikkanen JM, Singer LG, Kim SJ, et al. De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. Am J Resp Crit Care Med. 2016;194:596-606.
Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment―a consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38:493-503.
Cantu E, Diamond JM, Suzuki Y, et al. Quantitative evidence for revising the definition of primary graft dysfunction after lung transplant. Am J Resp Crit Care Med. 2018;197:235-243.
Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on primary lung graft dysfunction, part I: definition and grading-a 2016 consensus group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1097-1103.
Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Resp Crit Care Med. 2013;187:527-534.
Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016;35:397-406.
Verleden SE, Sacreas A, Vos R, Vanaudenaerde BM, Verleden GM. Advances in understanding bronchiolitis obliterans after lung transplantation. CHEST. 2016;150:219-225.
Courtwright A, Diamond JM, Wood I, et al. Detection and clinical impact of human leukocyte antigen antibodies in lung transplantation: a systematic review and meta-analysis. HLA. 2018;91:102-111.
Porteous MK, Diamond JM, Christie JD. Primary graft dysfunction: lessons learned about the first 72 hours after lung transplantation. Curr Opin Organ Transplant. 2015;20:506-514.
Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant. 2013;32:1034-1040.
Roux A, Bendib Le Lan I, Holifanjaniaina S, et al. Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics. Am J Transplant. 2016;16:1216-1228.
Visentin J, Bachelet T, Aubert O, et al. Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. Am J Transplant. 2020;20:1365-1374.
Bachelet T, Martinez C, Del Bello A, et al. Deleterious impact of donor-specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation. Transplantation. 2016;100:159-166.
Kayawake H, Chen-Yoshikawa TF, Gochi F, et al. Postoperative outcomes of lung transplant recipients with preformed donor-specific antibodies. Interact Cardiovasc Thorac Surg. 2020.
Thès J, Finet M, Couteau-Chardon A, et al. Impact on outcome of preoperative plasmapheresis in sensitized lung transplant recipients. J Heart Lung Transplant. 2020;39:S313.
Smith JD, Ibrahim MW, Newell H, et al. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation. J Heart Lung Transplant. 2014;33:1074-1082.
Safavi S, Robinson DR, Soresi S, Carby M, Smith JD. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2014;33:1273-1281.
Ius F, Verboom M, Sommer W, et al. Preemptive treatment of early donor-specific antibodies with IgA-and IgM-enriched intravenous human immunoglobulins in lung transplantation. Am J Transplant. 2018;18:2295-2304.